Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model

Figure 4

Xanthomicrol-retarded tumor progression in vivo. B16F10 melanoma cells were injected subcutaneously into the flanks of C57BL/6 mice. Treatments were initiated five days after tumor inoculation once a day via i.p. route for 21 consecutive days. Representative images of tumor mass in final day of the experiment (a). Tumor volumes were sized every other day (b), and tumor weights were measured after excisions of tumors in final day of the experiment (c). Data are represented as mean ± SEM (^∗ vs. vehicle treated mice).

(a)

(b)

(c)